Insider Trading Alert - SBRA, EXA And MNTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 8, 2015, 68 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,023.75 to $5,610,306.91.

Highlighted Stocks Traded by Insiders:

Sabra Health Care REIT (SBRA) - FREE Research Report

Ettl Robert A., who is Director at Sabra Health Care REIT, bought 3,500 shares at $27.95 on May 8, 2015. Following this transaction, the Director owned 37,455 shares meaning that the stake was boosted by 10.31% with the 3,500-share transaction.

The shares most recently traded at $27.77, down $0.18, or 0.65% since the insider transaction. Historical insider transactions for Sabra Health Care REIT go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 2,500
  • 24-Week # shares bought: 800
  • 24-Week # shares sold: 2,500

The average volume for Sabra Health Care REIT has been 408,400 shares per day over the past 30 days. Sabra Health Care REIT has a market cap of $1.7 billion and is part of the financial sector and real estate industry. Shares are down 8.07% year-to-date as of the close of trading on Friday.

Sabra Health Care REIT, Inc. operates as a real estate investment trust in the United States. The company, through its subsidiaries, owns and invests in real estate properties for the healthcare industry. The stock currently has a dividend yield of 5.59%. The company has a P/E ratio of 21.3. Currently, there are 5 analysts who rate Sabra Health Care REIT a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SBRA - FREE

TheStreet Quant Ratings rates Sabra Health Care REIT as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Sabra Health Care REIT Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exa (EXA) - FREE Research Report

Remondi Stephen A., who is CEO and President at Exa, sold 1,116 shares at $11.04 on May 8, 2015. Following this transaction, the CEO and President owned 496,974 shares meaning that the stake was reduced by 0.22% with the 1,116-share transaction.

The shares most recently traded at $11.17, up $0.13, or 1.16% since the insider transaction. Historical insider transactions for Exa go as follows:

  • 4-Week # shares bought: 12,000
  • 4-Week # shares sold: 8,884
  • 12-Week # shares bought: 12,000
  • 12-Week # shares sold: 28,884
  • 24-Week # shares bought: 12,000
  • 24-Week # shares sold: 58,884

The average volume for Exa has been 50,900 shares per day over the past 30 days. Exa has a market cap of $167.3 million and is part of the technology sector and computer software & services industry. Shares are down 1.37% year-to-date as of the close of trading on Thursday.

Exa Corporation develops, sells, and supports simulation software and services for vehicle manufacturers worldwide. Currently, there are 3 analysts who rate Exa a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXA - FREE

TheStreet Quant Ratings rates Exa as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Exa Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 493 shares at $19.05 on May 8, 2015. Following this transaction, the Senior VP, Pharmaceutical Scie owned 111,485 shares meaning that the stake was reduced by 0.44% with the 493-share transaction.

The shares most recently traded at $20.28, up $1.23, or 6.07% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 79,109
  • 12-Week # shares sold: 148,337
  • 24-Week # shares sold: 171,590

The average volume for Momenta Pharmaceuticals has been 982,800 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 60.47% year-to-date as of the close of trading on Friday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 4 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World